Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Entertainment
  • Software
  • Business
  • Education
  • Real Estate
Washingtoner

First Choice Neurology Pioneering Neurologists Administer the New FDA-Approved Drug Kisunla
Washingtoner/10263199

Trending...
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
  • Romanian Software Company ASSIST Software Ranks Second Nationally Among Large Enterprises in Its Category
Kisunla FDA Approved for Alzheimers
JUPITER, Fla. - Washingtoner -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the first physicians in the country to administer the newly FDA-approved drug Kisunla to patients. This groundbreaking development marks a significant milestone in neurological care, offering new hope to patients battling a range of neurological conditions.

Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.

More on Washingtoner
  • Coming Up on CNBC: Bilha Wachira Champions Financial Protection During Long-Term Care Awareness Month
  • Tacoma: Closures Projected to Allow for Arterial Work
  • Tacoma: Applicants Sought for the Bicycle Pedestrian Technical Advisory Group
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand

He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."

Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."

Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent.  We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."

More on Washingtoner
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • Stamp Me Launches Web App Ahead of 15th Anniversary
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
  • Spokane City Council Passes Chronic Nuisance Properties Ordinance
  • City of Spokane and City Council Announce 2027 Legislative Priorities

The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.

About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.

For more information about Kisunla and First Choice Neurology, visit fcneurology.com

Contact
First Choice Neurology
***@fcneurology.net


Source: First Choice Neurology
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
  • Kindering's 21st Luncheon Raises $220,000+ to Support Children with Disabilities and Their Families
  • Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
  • New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
  • Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration
  • Andrew Balzano Releases One of My Life's Passions: Classics and Mysteries, a Fan's Guide to Great Mysteries Worth Rewatching
  • Spokane: City Details Veterans Day Schedule
  • The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th
  • Romanian Software Company ASSIST Software Ranks Second Nationally Among Large Enterprises in Its Category
  • Washington Nurse Introduces Nightingale Care Hub to Help Families Organize Care
  • HIRO Ostomy Belt Launch by Richard O'Hamill
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • Flags Lowered for Spokane County Sheriff Deputies
  • Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
_catLbl0 _catLbl1

Popular on Washingtoner

  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 306
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 266
  • LocalsVoted Launches: Local Rankings From Phone-Verified Votes, Not Paid Placement - 163
  • Simpalm Staffing Launches Tax Preparer Staffing for U.S. CPA Firms - 135
  • Sycamore Dove Releases "Loving Every Moment" - 110
  • One in three Americans may have lost track of retirement savings from a previous job - 105
  • FloorLine Launches Live Shop Floor Tracking for Small Manufacturers - 103
  • Datavalet Named One of Quebec's Best Workplaces™ for 2026
  • Nextlink Internet Deploys netElastic to Modernize Its Hybrid Broadband Network
  • Tacoma: OMWBE Active Certification Class on November 16

Similar on Washingtoner

  • Green Revolution CBD Spotlights Its Water-Soluble Focus Tincture With CBD, CBG and Lion's Mane
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • Washington Nurse Introduces Nightingale Care Hub to Help Families Organize Care
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute